23.1 Polytrauma Resuscitation, Damage Control & Massive Transfusion

ABIM Critical Care Medicine Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Orientation: Format, Blueprint & Study Strategy

1.1 ABIM Critical Care Medicine Exam: Format, Blueprint & Study Strategy

2 Chapter 2: Acute Respiratory Failure & ARDS

2.1 ARDS Definition, Pathophysiology & Phenotypes 2.2 Lung-Protective Mechanical Ventilation 2.3 Refractory ARDS: Prone Positioning, Neuromuscular Blockade & VV-ECMO

3 Chapter 3: Obstructive Airways, Pulmonary Vascular & Pleural Emergencies

3.1 Severe Asthma & COPD Exacerbations in the ICU 3.2 Massive & Submassive Pulmonary Embolism 3.3 Pulmonary Hypertension & Right Ventricular Failure in the ICU 3.4 Massive Hemoptysis, Complex Pleural Effusions & Thoracic Drainage

4 Chapter 4: Airway, Parenchymal & Nonthrombotic Pulmonary Emergencies

4.1 Airway Management, Upper-Airway Obstruction & Artificial-Airway Complications 4.2 Diffuse Alveolar Hemorrhage, Interstitial Lung Disease, Pulmonary Vasculitis & Noncardiogenic Edema 4.3 Severe Community-Acquired & Viral Pneumonia 4.4 Nonthrombotic Embolism (Air, Fat, Amniotic Fluid, Tumor, Septic) & Acute Chest Syndrome

5 Chapter 5: Mechanical Ventilation Modes, Dyssynchrony & Liberation

5.1 Mechanical Ventilator Modes & Advanced Breath Delivery 5.2 Patient-Ventilator Dyssynchrony & Waveform Analysis 5.3 Ventilator Liberation, Spontaneous Breathing Trials & Post-Extubation Support

6 Chapter 6: Shock Syndromes & Hemodynamic Principles

6.1 Shock Classification, Cellular Pathophysiology & Biomarkers 6.2 Hemodynamic Monitoring: Arterial Lines, CVP & Pulmonary Artery Catheter 6.3 Dynamic Assessment of Fluid Responsiveness & Resuscitation Targets

7 Chapter 7: Vasoactive Therapies & Mechanical Circulatory Support

7.1 Vasopressors & Inotropes: Pharmacology & Clinical Titration 7.2 Temporary Mechanical Circulatory Support: IABP, Impella & TandemHeart 7.3 Venoarterial ECMO (VA-ECMO) & Differential Hypoxemia 7.4 Post-Cardiac Arrest Care, Targeted Temperature Management & Neuroprognostication

8 Chapter 8: Acute Kidney Injury & Renal Replacement Therapy

8.1 KDIGO AKI Classification, Etiologies & Diagnostic Evaluation 8.2 Continuous Renal Replacement Therapy (CRRT) vs Intermittent Hemodialysis 8.3 Indications & Timing for RRT in Critical Illness: AKIKI & STARRT-AKI

9 Chapter 9: Electrolyte, Acid-Base & Endocrine Emergencies

9.1 Severe Dysnatremias: Hyponatremia, Hypernatremia & Osmotic Demyelination 9.2 Potassium, Calcium, Magnesium & Phosphate Disorders 9.3 Complex & Mixed Acid-Base Disorders: Boston vs Copenhagen vs Stewart 9.4 Endocrine Crises: DKA, HHS, Thyroid Storm, Myxedema Coma & Adrenal Crisis

10 Chapter 10: Glycemic Control, Hyperammonemia, Pituitary & Adrenal Disorders

10.1 ICU Glycemic Control & Severe Hypoglycemia 10.2 Non-Hepatic Hyperammonemia & Metabolic Encephalopathy 10.3 Pituitary Emergencies, Adrenal Excess & Critical Illness-Related Corticosteroid Insufficiency

11 Chapter 11: Acute Coronary Syndromes & Cardiac Arrhythmias

11.1 Acute Coronary Syndromes & Mechanical Complications of Myocardial Infarction 11.2 Critical Tachyarrhythmias: Atrial Fibrillation with RVR, VT & VF 11.3 Critical Bradyarrhythmias, Conduction Blocks & Temporary Cardiac Pacing

12 Chapter 12: Acute Heart Failure, Valvular & Pericardial Emergencies

12.1 Acute Decompensated Heart Failure & Cardiogenic Pulmonary Edema 12.2 Acute Valvular Regurgitation & Prosthetic Valve Emergencies 12.3 Pericardial Tamponade & Acute Aortic Syndromes

13 Chapter 13: Myocardial Disease, Hypertensive & Cardiac Device Emergencies

13.1 Fulminant Myocarditis, Stress & Peripartum Cardiomyopathy, and Hypertrophic Cardiomyopathy 13.2 Hypertensive Emergencies & Ruptured Abdominal Aortic Aneurysm 13.3 Implanted Cardiac Devices, LVAD Emergencies & Electrical Storm

14 Chapter 14: Sepsis & Systemic Infectious Diseases

14.1 Sepsis-3 Definitions & Surviving Sepsis Campaign 2026 Guidelines 14.2 Refractory Septic Shock & Adjunctive Therapies 14.3 Multidrug-Resistant Pathogens & Antimicrobial Stewardship in the ICU

15 Chapter 15: ICU-Acquired & Severe Focal Infections

15.1 Hospital-Acquired & Ventilator-Associated Pneumonia 15.2 Central Line-Associated Bloodstream Infections & Catheter-Associated UTIs 15.3 Intra-Abdominal Sepsis, Necrotizing Soft Tissue Infections & CNS Infections

16 Chapter 16: Focal, Special-Host & Systemic Infections

16.1 CNS Infections Beyond Bacterial Meningitis: Encephalitis, Brain Abscess & Epidural Abscess 16.2 Infections in the Immunocompromised Host, Tropical & Bioterror Infections 16.3 Infective Endocarditis, Device Infections & Other Focal Cardiovascular Infections 16.4 Antimicrobial Pharmacokinetics, Allergy, Toxicity & Infection Prevention 16.5 Gastrointestinal & Hepatobiliary Infections: Fulminant C. difficile, Typhlitis, CMV Colitis & Abscesses

17 Chapter 17: Neurocritical Care & Coma

17.1 Coma, Altered Mental Status & Acute Delirium in the ICU 17.2 Status Epilepticus & Non-Convulsive Status Epilepticus 17.3 Acute Ischemic Stroke & Intracranial Hemorrhage

18 Chapter 18: Cerebrovascular Syndromes, Encephalopathy & Withdrawal States

18.1 Cerebral Venous Sinus Thrombosis, PRES & Reversible Cerebral Vasoconstriction Syndrome 18.2 Alcohol & Sedative Withdrawal, Wernicke Encephalopathy & Drug-Induced Encephalopathy

19 Chapter 19: Intracranial Hypertension & Neuromuscular Weakness

19.1 Intracranial Pressure Monitoring, Cerebral Perfusion & Tiered ICP Management 19.2 Acute Neuromuscular Respiratory Failure, ICU-Acquired Weakness & Brain Death Determination

20 Chapter 20: Traumatic Brain Injury, Spinal Cord Injury & Toxin-Mediated Paralysis

20.1 Traumatic Brain Injury Management & Paroxysmal Sympathetic Hyperactivity 20.2 Acute Spinal Cord Injury, Neurogenic Shock & Autonomic Dysreflexia 20.3 Toxin-Mediated Paralysis & Neuromuscular Crises: Botulism, Tetanus, Tick Paralysis & Myasthenic Crisis

21 Chapter 21: Gastrointestinal, Hepatic & Abdominal Emergencies

21.1 Acute Upper & Lower Gastrointestinal Bleeding in the ICU 21.2 Acute Liver Failure & Severe Acute Pancreatitis 21.3 Abdominal Compartment Syndrome & Acute Mesenteric Ischemia

22 Chapter 22: Luminal GI Emergencies & Complications of Cirrhosis

22.1 Esophageal, Gastric & Bowel Emergencies: Perforation, Obstruction, Ogilvie Syndrome & Colonic Ischemia 22.2 Complications of Cirrhosis: Alcohol-Associated Hepatitis, Hepatorenal Syndrome & Pulmonary Vascular Syndromes

23 Chapter 23: Trauma, Burns & Perioperative Critical Care

23.1 Polytrauma Resuscitation, Damage Control & Massive Transfusion 23.2 Severe Burn Injury, Inhalation Injury & Environmental Emergencies 23.3 Perioperative Critical Care for High-Risk Surgical Patients

24 Chapter 24: Thoracic Trauma, Environmental Injury & Obstetric Critical Care

24.1 Thoracic Trauma: Flail Chest, Pulmonary Contusion, Great Vessel & Tracheobronchial Injury 24.2 Environmental Injury: Drowning, Diving, Altitude, Heat, Cold, Electrical & Radiation 24.3 Obstetric & Genitourinary Emergencies and the Physiology of Pregnancy

25 Chapter 25: Transplantation, Donor Management & Post-Cardiac Surgery Care

25.1 Solid Organ Transplant Recipients & Deceased Donor Management 25.2 Post-Cardiac Surgery Critical Care: Bleeding, Tamponade, Low Output & Vasoplegia

26 Chapter 26: Hematologic Emergencies, Toxicology, Critical Ultrasound & ICU Liberation

26.1 Hematologic Emergencies in the ICU: HIT, DIC, TMA & Anticoagulant Reversal 26.2 Critical Care Toxicology, Toxidromes & Specific Antidotes 26.3 Critical Care Point-of-Care Ultrasound (POCUS) 26.4 ICU Liberation, Analgosedation, Goals of Care & Critical Care Ethics

27 Chapter 27: Transfusion Medicine, Hematologic & Oncologic Disorders

27.1 Transfusion Medicine: Products, Thresholds, Reactions & Apheresis 27.2 Red and White Cell Disorders, Hemoglobinopathies, Factor Deficiencies & Hypercoagulable States 27.3 Oncologic Emergencies, Hematopoietic Cell Transplant Complications & Cellular Therapy Toxicity

28 Chapter 28: Clinical Pharmacology, Adverse Drug Reactions & Specific Poisonings

28.1 Pharmacokinetic Principles, Dose Adjustment & Drug Interactions in Critical Illness 28.2 Adverse Drug Reactions: Anaphylaxis, Severe Cutaneous Reactions & Hyperthermic Syndromes 28.3 Specific Poisonings: Sodium-Channel Blockers, Lithium, Valproate, Theophylline, Iron, Sulfonylureas & Methemoglobinemia

29 Chapter 29: Ethics, Research Methods, Administration & Abdominal Ultrasound

29.1 Advance Care Planning, Nonbeneficial Treatment, Informed Consent & Confidentiality 29.2 Critical Care Research Methods, Statistics, IRB Oversight & Quality Improvement 29.3 Abdominal, Vascular & Procedural Point-of-Care Ultrasound

23.1 Polytrauma Resuscitation, Damage Control & Massive Transfusion

Key Takeaways Explain This Topic AI

The trauma lethal triad consists of hypothermia (< 35°C), acidosis (arterial pH < 7.20, base deficit > 6 mEq/L), and coagulopathy; each derangement compounds the others, with enzymatic clotting factor activity and platelet function falling exponentially below physiological temperature and pH.

Damage Control Resuscitation (DCR) employs permissive hypotension (target SBP 80-90 mmHg, MAP 50-60 mmHg) to prevent disrupting provisional clots ('popping the clot') until surgical or endovascular hemostasis is secured; however, severe Traumatic Brain Injury (TBI) is an absolute contraindication requiring target SBP >= 100-110 mmHg to preserve cerebral perfusion.

Massive Transfusion Protocol (MTP) activation should be guided by objective scores (e.g., ABC score >= 2 or Shock Index > 1.0) and utilizes a balanced 1:1:1 ratio of packed red blood cells, fresh frozen plasma, and platelets; the PROPPR trial demonstrated that 1:1:1 significantly decreases 24-hour exsanguination mortality compared to 1:1:2.

Viscoelastic hemostatic assays (TEG/ROTEM) guide goal-directed resuscitation: prolonged R-time/CT indicates factor deficiency treated with FFP or 4F-PCC; decreased alpha angle/CFT indicates hypofibrinogenemia treated with cryoprecipitate; decreased MA/MCF indicates platelet deficit treated with platelets; and elevated LY30/ML indicates hyperfibrinolysis treated with tranexamic acid.

Tranexamic acid (TXA) reduces all-cause and bleeding mortality when administered within 3 hours of trauma (CRASH-2/CRASH-3 dosing: 1 g IV over 10 minutes then 1 g IV over 8 hours); administration beyond 3 hours increases mortality and is strictly contraindicated. Citrate in blood products chelates ionized calcium, requiring frequent replacement to maintain ionized calcium >= 1.1-1.3 mmol/L.

Last updated: October 2026

The Lethal Triad and Trauma-Induced Coagulopathy

Exsanguinating trauma remains a leading cause of preventable mortality in critical care medicine. When severe tissue injury combines with systemic hypoperfusion, patients rapidly enter a self-propagating downward spiral historically known as the lethal triad of trauma : hypothermia , acidosis , and coagulopathy . Uninterrupted, this triad culminates in physiological exhaustion and death.

1. Hypothermia

Hypothermia in trauma is defined as a core body temperature < 35 ∘ C < 35^\circ\text{C} < 3 5 ∘ C ( < 95 ∘ F < 95^\circ\text{F} < 9 5 ∘ F ). It arises from environmental exposure, loss of thermoregulatory shivering due to shock or sedation, administration of cold intravenous crystalloids and uncrossed blood products, and impaired metabolic heat production from cellular hypoperfusion. Coagulation is an enzymatic cascade: for every 1 ∘ C 1^\circ\text{C} 1 ∘ C reduction in core body temperature, the activity of clotting factor complexes declines by approximately 10%. Below 33 ∘ C 33^\circ\text{C} 3 3 ∘ C , platelet adhesion and aggregation are severely blunted due to decreased glycoprotein Ib-IX-V complex binding to von Willebrand factor, even though standard laboratory coagulation tests (PT, aPTT, INR) performed in central laboratories at a standardized 37 ∘ C 37^\circ\text{C} 3 7 ∘ C will mask this in vivo enzymatic paralysis.

2. Metabolic Acidosis

Systemic tissue hypoperfusion forces cellular metabolism into anaerobic glycolysis, generating profound lactic acidosis with an arterial pH < 7.20 \text{pH} < 7.20 pH < 7.20 and a base deficit > 6 mEq/L > 6\text{ mEq/L} > 6 mEq/L . Hydrogen ions directly inhibit the enzymatic activity of the tenase (Factor VIIIa/IXa) and prothrombinase (Factor Va/Xa) complexes on the activated platelet phospholipid surface. At a pH of 7.0, thrombin generation falls by more than 50%, and when combined with hypothermia ( < 33 ∘ C < 33^\circ\text{C} < 3 3 ∘ C ), thrombin generation kinetics are suppressed by up to 80%. Acidosis also accelerates the degradation of fibrinogen and destabilizes established clot architecture.

3. Trauma-Induced Coagulopathy (TIC)

Modern understanding recognizes that trauma coagulopathy is not simply a late consequence of dilution and factor consumption, but an early, primary endogenous phenomenon termed Trauma-Induced Coagulopathy (TIC) . Driven by extensive tissue injury and cellular shock, TIC involves:

Endothelial Glycocalyx Degradation : Massive sympathoadrenal activation and shear stress shed syndecan-1 and heparin sulfate proteoglycans into the circulation, causing endogenous auto-heparinization.

Protein C Activation : Thrombomodulin upregulation by hypoxic endothelium binds thrombin to activate Protein C, which irreversibly inactivates Factors Va and VIIIa.

Hyperfibrinolysis : Ischemic tissues release excessive tissue-type plasminogen activator (tPA) while consuming plasminogen activator inhibitor-1 (PAI-1), triggering premature clot dissolution.

Platelet Dysfunction : Circulating platelets exhibit marked receptor exhaustion and unresponsiveness to thrombin and ADP stimulation despite adequate numerical counts.

Damage Control Philosophy: Surgery vs. Resuscitation

Traditional trauma management emphasized early, exhaustive anatomical reconstruction during the index operative encounter. However, prolonged surgeries in the setting of severe hypothermia, acidosis, and coagulopathy invariably caused intraoperative death. This led to the modern paradigm of Damage Control Surgery (DCS) and its medical counterpart, Damage Control Resuscitation (DCR) .

Damage Control Surgery (DCS)

Damage control surgery prioritizes physiological survival over anatomical completeness. It progresses through three distinct, coordinated stages:

Stage I (Abbreviated Surgery) : Rapid laparotomy or thoracotomy focused solely on controlling surgical hemorrhage (ligation, vascular shunts, balloon tamponade, perihepatic packing) and gross enteral contamination (stapling off bowel perforations without anastomosis). The fascia is left open, and temporary abdominal closure (such as negative pressure wound therapy or a Bogota bag) is placed.

Stage II (ICU Resuscitation) : The patient is transported directly to the intensive care unit for aggressive core rewarming, correction of coagulopathy, reversal of acidosis, and restoration of physiological reserve.

Stage III (Definitive Reconstruction) : Once the lethal triad is fully resolved (typically 24 to 48 hours later), the patient returns to the operating room for pack removal, formal vascular reconstruction, gastrointestinal continuity restoration, and abdominal wall closure.

Damage Control Resuscitation (DCR)

Damage control resuscitation begins in the prehospital or trauma bay setting and continues in the ICU. Its three core tenets are:

Permissive Hypotension : Restricting fluid administration until active surgical or endovascular bleeding is controlled.

Hemostatic Resuscitation : Prioritizing balanced, uncrossed blood products (plasma, platelets, RBCs) over large-volume crystalloids.

Early Damage Control Adjuncts : Rapid administration of tranexamic acid, empirical calcium replacement, and aggressive active core rewarming.

Permissive Hypotension: Principles and Absolute Contraindications

Permissive hypotension (also termed hypotensive resuscitation or balanced hypovolemia) deliberately targets a lower-than-normal blood pressure during active non-compressible torso hemorrhage. The physiological targets are:

• Systolic Blood Pressure (SBP) : 80 to 90 mmHg 80\text{ to }90\text{ mmHg} 80 to 90 mmHg
• Mean Arterial Pressure (MAP) : 50 to 60 mmHg 50\text{ to }60\text{ mmHg} 50 to 60 mmHg
• Physiological Rationale

Aggressive infusion of intravenous crystalloids or excessive blood products to reach "normal" blood pressures ( > 120 mmHg > 120\text{ mmHg} > 120 mmHg ) increases mechanical hydrostatic pressure across newly formed, friable vascular clots, dislodging them—a lethal clinical pitfall colloquially known as "popping the clot" . Furthermore, large-volume crystalloids (0.9% normal saline or Lactated Ringer's) dilute circulating clotting factors, cool the patient, induce hyperchloremic metabolic acidosis, and accelerate endothelial glycocalyx shedding.

Warning

The Severe Traumatic Brain Injury (TBI) Exception : Permissive hypotension is absolutely contraindicated in patients with concurrent moderate-to-severe Traumatic Brain Injury (GCS ≤ 8 \le 8 ≤ 8 or evidence of intracranial hemorrhage/mass effect). In severe TBI, cerebral autoregulation is impaired or absent, rendering Cerebral Blood Flow (CBF) entirely dependent on Cerebral Perfusion Pressure ( CPP = MAP − ICP \text{CPP} = \text{MAP} - \text{ICP} CPP = MAP − ICP ). Brain Trauma Foundation guidelines mandate maintaining SBP ≥ 100 mmHg \ge 100\text{ mmHg} ≥ 100 mmHg (ages 50–69) or ≥ 110 mmHg \ge 110\text{ mmHg} ≥ 110 mmHg (ages 15–49 or ≥ 70 \ge 70 ≥ 70 ), targeting MAP ≥ 80 mmHg \ge 80\text{ mmHg} ≥ 80 mmHg to sustain CPP ≥ 60 to 70 mmHg \text{CPP} \ge 60\text{ to }70\text{ mmHg} CPP ≥ 60 to 70 mmHg . Even a single brief episode of SBP < 90 mmHg < 90\text{ mmHg} < 90 mmHg in severe TBI doubles mortality.

Massive Transfusion Protocols and the Balanced 1:1:1 Strategy

A Massive Transfusion Protocol (MTP) is an emergency institutional delivery mechanism designed to release pre-thawed plasma, platelets, and packed red blood cells in fixed, physiological ratios to combat trauma-induced coagulopathy and hemorrhagic shock.

Definitions of Massive Transfusion

Historical: Transfusion of ≥ 10 \ge 10 ≥ 10 units of Packed Red Blood Cells (PRBCs) within a 24-hour period.

Contemporary (Dynamic): Transfusion of > 4 > 4 > 4 units of PRBCs within 1 hour with anticipated ongoing bleeding, or replacement of > 50 % > 50\% > 50% of total circulating blood volume within 3 hours.

MTP Activation Triggers and Scoring Systems

Early activation before laboratory results return is critical. Validated clinical scoring tools include:

Assessment of Blood Consumption (ABC) Score : Evaluates 4 bedside parameters (1 point each):

• Penetrating trauma mechanism
• Arrival SBP ≤ 90 mmHg \le 90\text{ mmHg} ≤ 90 mmHg
• Arrival Heart Rate ≥ 120 bpm \ge 120\text{ bpm} ≥ 120 bpm
• Positive Focused Assessment with Sonography for Trauma (FAST)

An ABC score ≥ 2 \ge 2 ≥ 2 triggers immediate MTP activation with a sensitivity of ~75% and specificity of ~85%.

Shock Index (SI) : Heart Rate divided by SBP. A Shock Index > 1.0 \text{Shock Index} > 1.0 Shock Index > 1.0 (normal 0.5 to 0.7 0.5\text{ to }0.7 0.5 to 0.7 ) indicates severe occult hypovolemia and independently predicts massive transfusion need.

The Balanced 1:1:1 Resuscitation Paradigm (The PROPPR Trial)

Historically, trauma patients received large volumes of crystalloid followed by PRBCs, with plasma and platelets added only after laboratory coagulopathy emerged. This approach led to severe dilutional coagulopathy.

The landmark PROPPR Trial (Pragmatic, Randomized Optimal Platelet and Plasma Ratios; JAMA 2015) randomized 680 severely bleeding trauma patients to a balanced 1:1:1 ratio (1 unit of platelets : 1 unit of FFP : 1 unit of PRBCs) versus a 1:1:2 ratio (1 unit of platelets : 1 unit of FFP : 2 units of PRBCs). While overall 24-hour and 30-day all-cause mortality did not differ significantly as the primary endpoint, the 1:1:1 group achieved significantly faster anatomical hemostasis (86% vs. 78%, p = 0.006 p=0.006 p = 0.006 ) and demonstrated a significant reduction in mortality from exsanguination within the first 24 hours (9.2% vs. 14.6%, p = 0.03 p=0.03 p = 0.03 ). Consequently, modern guidelines endorse a balanced 1:1:1 ratio as standard practice.

Viscoelastic Hemostatic Assays: TEG and ROTEM

Standard laboratory tests (PT/INR, aPTT, fibrinogen) are performed on platelet-poor plasma, take 45–60 minutes to process, and fail to assess platelet-fibrin interactions or hyperfibrinolysis. Viscoelastic Hemostatic Assays (VHAs) —predominantly Thromboelastography (TEG) and Rotational Thromboelastometry (ROTEM) —provide real-time, whole-blood dynamic evaluations of clot initiation, propagation, tensile strength, and dissolution within 10 to 20 minutes, enabling targeted, goal-directed factor replacement.

Viscoelastic Parameters and Product Matching

Stage of Clotting TEG Parameter (Normal Value) ROTEM Parameter (Normal Value) Underlying Coagulation Process Targeted Product Replacement

Clot Initiation R-time (Reaction Time: 5–10 min) CT (Clotting Time: 100–240 s) Enzymatic thrombin generation & clotting factor activation Fresh Frozen Plasma (FFP) (10–15 mL/kg) or 4-Factor PCC

Clot Propagation Alpha Angle ( α \alpha α ) (53–72°) & K-time (1–3 min) CFT (Clot Formation Time: 70–150 s) & α \alpha α angle Thrombin burst, fibrin polymerization kinetics & cleavage Cryoprecipitate (10 units or 1–2 pools) or Fibrinogen Concentrate

Maximum Clot Strength MA (Maximum Amplitude: 50–70 mm) MCF (Maximum Clot Firmness: 50–72 mm) Platelet-fibrin mesh crosslinking (80% platelets, 20% fibrinogen) Platelets (1 apheresis pack) ± \pm ± Cryoprecipitate if fibrinogen low

Clot Dissolution / Lysis LY30 (Lysis at 30 min: 0–3%) ML (Maximum Lysis: < 15 % < 15\% < 15% ) Fibrinolysis mediated by plasmin cleavage of fibrin polymers Tranexamic Acid (TXA) (1 g IV bolus over 10 min, then 1 g over 8 h)

Tip

Viscoelastic Trap : A severely decreased Maximum Amplitude (MA on TEG or MCF on ROTEM) reflects both platelet deficiency/dysfunction and severe hypofibrinogenemia. To differentiate, check the functional fibrinogen track (TEG Functional Fibrinogen or ROTEM FIBTEM). If the FIBTEM MCF is < 10 to 12 mm < 10\text{ to }12\text{ mm} < 10 to 12 mm , replace fibrinogen with cryoprecipitate before or alongside platelet transfusion.

Tranexamic Acid: Evidence, Dosing, and the Critical 3-Hour Window

Tranexamic Acid (TXA) is a synthetic lysine analogue that competitively binds to lysine-binding sites on plasminogen molecules, blocking plasminogen from interacting with fibrin and preventing conversion to active plasmin, thereby suppressing fibrinolysis.

Clinical Evidence: CRASH-2 and CRASH-3

CRASH-2 Trial ( Lancet 2010): Enrolled 20,211 adult trauma patients with significant hemorrhage (SBP < 90 mmHg < 90\text{ mmHg} < 90 mmHg or HR > 110 bpm > 110\text{ bpm} > 110 bpm ) within 8 hours of injury. Early TXA administration significantly reduced all-cause mortality (14.5% vs. 16.0%, p = 0.0035 p=0.0035 p = 0.0035 ) and bleeding mortality (4.9% vs. 5.7%, p = 0.0077 p=0.0077 p = 0.0077 ) without increasing vascular occlusive events (DVT/PE, stroke, MI).

CRASH-3 Trial ( Lancet 2019): Evaluated TXA in isolated traumatic brain injury within 3 hours. TXA significantly reduced head-injury-related death in mild-to-moderate TBI (GCS 9–15), though patients with severe TBI (GCS 3–8) or bilaterally unreactive pupils derived no clear survival benefit.

The 3-Hour Time Window

Subgroup analysis from CRASH-2 revealed that the timing of TXA administration is paramount:

TXA administered within < 1 hour < 1\text{ hour} < 1 hour of injury reduced bleeding death risk by ~32% ( p < 0.001 p<0.001 p < 0.001 ).

TXA administered within 1 to 3 hours reduced bleeding death risk by ~21% ( p = 0.03 p=0.03 p = 0.03 ).

TXA administered AFTER 3 hours increased the risk of death due to bleeding (RR 1.44, 95% CI 1.12–1.84, p = 0.004 p=0.004 p = 0.004 ) and carries an elevated risk of microvascular thrombosis.

Note

Standard Dosing Regimen : 1 g 1\text{ g} 1 g IV bolus infused over 10 minutes, followed immediately by a continuous intravenous infusion of 1 g 1\text{ g} 1 g over 8 hours. Rapid bolus infusion faster than 10 minutes can induce transient systemic hypotension.

Transfusion Complications: Citrate Toxicity and Ionized Hypocalcemia

Massive transfusion introduces significant metabolic and physiological derangements that must be managed concurrently:

Citrate Toxicity and Hypocalcemia

All commercial blood products are anticoagulated with citrate (sodium citrate and citric acid), which prevents clotting by chelating free ionized calcium ( Ca 2 + \text{Ca}^{2+} Ca 2 + ). A healthy liver rapidly metabolizes citrate to bicarbonate. However, in trauma patients suffering from hypothermia, hepatic hypoperfusion, and shock, citrate clearance drops precipitously, resulting in severe ionized hypocalcemia ( iCa 2 + < 0.9 mmol/L \text{iCa}^{2+} < 0.9\text{ mmol/L} iCa 2 + < 0.9 mmol/L ).

Clinical Consequences : Ionized calcium is Factor IV in the coagulation cascade; without adequate iCa 2 + \text{iCa}^{2+} iCa 2 + , assembly of the tenase and prothrombinase complexes fails, rendering coagulation non-functional regardless of administered factor volumes. Hypocalcemia also blunts cardiac myocyte contractility, induces peripheral vasodilation, causes refractory hypotension, and prolongs the QTc interval, predisposing to polymorphic ventricular arrhythmias.

Management Target : Ionized calcium must be checked every 30 to 60 minutes during active MTP resuscitation. Clinicians should empirically administer 1 to 2 g 1\text{ to }2\text{ g} 1 to 2 g of intravenous calcium chloride (or 3 g 3\text{ g} 3 g calcium gluconate) for every 4 units of citrated blood components transfused, titrating to maintain iCa 2 + ≥ 1.1 to 1.3 mmol/L \text{iCa}^{2+} \ge 1.1\text{ to }1.3\text{ mmol/L} iCa 2 + ≥ 1.1 to 1.3 mmol/L . Calcium chloride contains three times more elemental calcium per gram than calcium gluconate and does not require hepatic metabolism, making it the preferred formulation in central venous access.

Other MTP Complications

Hyperkalemia : Red blood cells leak intracellular potassium during refrigerated storage. Rapid transfusion of multiple units can trigger life-threatening hyperkalemia ( > 6.5 mEq/L > 6.5\text{ mEq/L} > 6.5 mEq/L ), especially with concurrent renal hypoperfusion and acidosis.

Hypothermia : Blood products are stored at 1 ∘ C 1^\circ\text{C} 1 ∘ C to 6 ∘ C 6^\circ\text{C} 6 ∘ C . Rapid blood warmers (e.g., Belmont, Level 1) capable of delivering 40 ∘ C 40^\circ\text{C} 4 0 ∘ C to 42 ∘ C 42^\circ\text{C} 4 2 ∘ C fluids at high flow rates ( > 500 mL/min > 500\text{ mL/min} > 500 mL/min ) are mandatory to prevent worsening core hypothermia.

Massive Transfusion Protocol Targets

Clinical Parameter Target Threshold during Active MTP Diagnostic / Monitoring Modality

Permissive SBP (No TBI) 80 to 90 mmHg 80\text{ to }90\text{ mmHg} 80 to 90 mmHg (MAP 50 to 60 mmHg 50\text{ to }60\text{ mmHg} 50 to 60 mmHg ) Arterial line transducer

SBP in Concomitant TBI ≥ 100 to 110 mmHg \ge 100\text{ to }110\text{ mmHg} ≥ 100 to 110 mmHg (MAP ≥ 80 mmHg \ge 80\text{ mmHg} ≥ 80 mmHg ) Arterial line transducer

Core Body Temperature > 35.0 ∘ C > 35.0^\circ\text{C} > 35. 0 ∘ C (ideally > 36.0 ∘ C > 36.0^\circ\text{C} > 36. 0 ∘ C ) Continuous esophageal or bladder temperature probe

Arterial Blood Gas pH > 7.25 to 7.30 > 7.25\text{ to }7.30 > 7.25 to 7.30 (Base Deficit < 4 mEq/L < 4\text{ mEq/L} < 4 mEq/L ) Serial arterial blood gas every 30–60 min

Ionized Calcium ( iCa 2 + \text{iCa}^{2+} iCa 2 + ) ≥ 1.10 to 1.30 mmol/L \ge 1.10\text{ to }1.30\text{ mmol/L} ≥ 1.10 to 1.30 mmol/L Point-of-care blood gas or electrolyte co-oximeter

Hemoglobin 7.0 to 9.0 g/dL 7.0\text{ to }9.0\text{ g/dL} 7.0 to 9.0 g/dL Point-of-care or laboratory blood count

Fibrinogen ≥ 150 to 200 mg/dL \ge 150\text{ to }200\text{ mg/dL} ≥ 150 to 200 mg/dL Clauss fibrinogen assay or TEG Functional Fibrinogen / ROTEM FIBTEM

Platelet Count ≥ 50 , 000 / μ L \ge 50,000/\mu\text{L} ≥ 50 , 000/ μ L ( ≥ 100 , 000 / μ L \ge 100,000/\mu\text{L} ≥ 100 , 000/ μ L with severe TBI) Complete blood count or TEG MA / ROTEM MCF

Serum Potassium 3.5 to 5.0 mEq/L 3.5\text{ to }5.0\text{ mEq/L} 3.5 to 5.0 mEq/L Point-of-care electrolyte testing